12.01.06
HBI Acquires Sambucol
A new company, Healthcare Brands International (HBI), was recently launched to turn innovative medical product technology into successful consumer brands. Backed by £25 million of venture capital from a syndicate of leading life science investors, HBI is targeting companies that have successfully developed innovative technology but lack the commercial capability and resources to realize their true potential with consumers worldwide. The 10-strong team has more than 100 combined years of experience in identifying and commercializing new and unique healthcare product and brand opportunities. The elderberry extract Sambucol is HBI’s first brand. Virologist Dr. Madeleine Mumcuoglu identified and developed a unique process for the extraction of an active ingredient in elderberry with antiviral properties that, amongst other benefits, helps combat the symptoms of influenza.
A new company, Healthcare Brands International (HBI), was recently launched to turn innovative medical product technology into successful consumer brands. Backed by £25 million of venture capital from a syndicate of leading life science investors, HBI is targeting companies that have successfully developed innovative technology but lack the commercial capability and resources to realize their true potential with consumers worldwide. The 10-strong team has more than 100 combined years of experience in identifying and commercializing new and unique healthcare product and brand opportunities. The elderberry extract Sambucol is HBI’s first brand. Virologist Dr. Madeleine Mumcuoglu identified and developed a unique process for the extraction of an active ingredient in elderberry with antiviral properties that, amongst other benefits, helps combat the symptoms of influenza.